Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30150914 | 1.00 | IDO1 (0.44) | IDO1PDPK1HTR6CA1CA2 | |
| SCHEMBL2773405 | 0.89 | ALDH1A1 (0.49) | IDO1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL3114732 | 0.81 | HTR2A (0.42) | IDO1PDPK1HTR6CA1CA2 | |
| SCHEMBL29024729 | 0.79 | RAB9A (0.46) | IDO1PDPK1HTR6CA1CA2 | |
| SCHEMBL4609282 | 0.78 | PDPK1 (0.47) | IDO1PDPK1CA1CA2CYP11B2 | |
| SCHEMBL2215028 | 0.78 | CYP19A1 (0.46) | KDM4EALDH1A1SIGMAR1RAB9A | |
| SCHEMBL5083382 | 0.74 | PDPK1 (0.47) | IDO1PDPK1HTR6CYP11B2PIN1 | |
| SCHEMBL28118233 | 0.74 | ESR2 (0.47) | CA1CA2 | |
| SCHEMBL11118897 | 0.74 | PDPK1 (0.56) | PDPK1HTR6CA1CA2KDM4E | |
| SCHEMBL3348739 | 0.72 | ACP3 (0.41) | IDO1PDPK1KDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103910718-B | Double cyclosubstituted pyrazolone azo compounds, preparation method and use | 齐鲁制药有限公司 | 2018-08-14 | — | — | CN | disclosed |
| CN-103619814-A | Novel amino-pyrroline derivatives and their use in the prevention and/or treatment of metabolic syndrome | UNIV STRASBOURG | 2014-03-05 | — | — | CN | disclosed |
| EP-2630141-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2013-08-28 | — | — | EP | disclosed |
| CN-103153989-A | Cathepsin s inhibitor compounds | LILLY CO ELI | 2013-06-12 | — | — | CN | disclosed |
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2012054315-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
| US-6949575-B2 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives | PFIZER INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1284958-B1 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS USING AMINOIDANE DERIVATIVES | WARNER LAMBERT CO (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20030220382-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives | BARTA NANCY SUE (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1284958-A1 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS USING AMINOIDANE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-0650476-B1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMA CO LTD (JP) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001083425-A1 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS USING AMINOINDANE DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2001-11-08 | — | — | WO | disclosed |
| US-6136826-A | AMINOPIPERIDINE COMPOUNDS SUBSTITUTED WITH ALKANOYL | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| CN-1052224-C | Peripheral Vasodilating agent containing N-acylated 4-amino piperidine derivatives as active ingredients | OTSUKA PHARMA CO LTD (JP) | 2000-05-10 | — | — | CN | disclosed |
| US-5760058-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5656642-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | CTSS, CTSZ, CTSV | IDO1 1372/4885PDPK1 2540/4885HTR6 4307/4885 |
| US-20030220382-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives | APP, APBA1, PSEN1 | IDO1 407/4885PDPK1 3204/4885HTR6 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.